1. Fogelman I, Gnanasegaran G, van der Wall H. (Eds). Radionuclide and hybrid bone imaging. 2012.
2. Padhani AR, Lecouvet FE, Tunaric N, et al. Rationale for modernising imaging in advanced prostate cancer. European urology focus. 2017;3(2-3);223-239.
3. Provan D. (ed). Oxford handbook of clinical and laboratory investigation. 2018.
4. Bastawrous S, Bhargava P, Behnia F, et al. Newer PET application with an old tracer: role of 18F-NaD skeletal PET/CT in oncologic practice. Radiographics. 2014;34:1295-1316.
5. Talbot JN, Paycha F, Balogova S. Diagnosis of bone metastasis: recent comparative studies of imaging modalities. Q J Nucl Med Mol Imaging. 2011;55(4):371-410.
6. Cheng X, Li Y, Xu Z, et al. Comparison of 18F-FDG PET/CT with bone scintigraphy for detection of bone metastasis: a meta-analysis. Acta Radiolol. 2011;52(7):779-787.
7. Vaz S, Usmani S, Gnanasegaran G, Van den Wyngaert T. Molecular imaging of bone metastases using bone targeted tracers. Q J Nucl Med Mol Imaging. 2019;63(2):112-128.
8. Beheshti M, Langsteger W, Fogelman I. Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med. 2009;39(6):396-407.
9. Cook GJR. PET and PET/CT imaging of skeletal metastases. Cancer Imaging. 2010;10(1):153-160.
10. Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014;43(11):1503-1513.
11. Beheshti M, Rezaee A, Geinitz H, et al. Evaluation of prostate cancer bone metatases with 18F-NaF and 18F-Fluorocholine PET/CT. J Nucl Med. 2016;57(Suppl 3):55S-60S.
12. Evangelista L, Cimitan M, Zattoni F, et al. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A restrospective analysis. Scand J Urol. 2015;49(5):345-353.
13. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486-495.
14. Lengana T, Lawal IO, Boshomane TG, et al. 68Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli? Clin Genitourin Cancer. 2018;16(5):392-401.
15. Dyrberg E, Hendel HW, Huynh THV, et al. 68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study. Eur Radiol. 2019;293(3):1221-1230.